Want to see RMD full AI Analyst Report?
RMD Stock Chart & Stats
$228.12
-$0.23(-0.10%)
At close: 4:00 PM EST
$228.12
-$0.23(-0.10%)
Day’s Range― - ―
52-Week Range$180.27 - $293.81
Previous CloseN/A
Volume178.41K
Average Volume (3M)1.53M
Market Cap
$28.27B
Enterprise Value$26.21B
Total Cash (Recent Filing)$1.66B
Total Debt (Recent Filing)$843.17M
Price to Earnings (P/E)18.7
Beta0.56
Next Earnings
Aug 06, 2026EPS Estimate
2.9Next Dividend Ex-DateN/A
Dividend Yield0.92%
Share Statistics
EPS (TTM)10.38
Shares Outstanding145,056,380
10 Day Avg. Volume1,515,784
30 Day Avg. Volume1,532,202
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)6.34
Price to Sales (P/S)7.36
P/FCF Ratio22.78
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit7.67
Enterprise Value/Ebitda11.99
Forecast
1Y Price Target
$256.09Price Target Upside12.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)12.24
Revenue Forecast (FY)$6.08B
Bulls Say, Bears Say
Bulls Say
High Profitability And Margin ProfileSustained high gross and net margins indicate durable pricing power and product mix advantages in sleep/respiratory devices. Elevated margins support reinvestment, R&D, dividends and buybacks, and provide a buffer against cost shocks while enabling long-term margin-accretion targets through 2030.
Strong Cash Generation And Low LeverageConsistent operating cash flow well above net income and a conservative debt profile give ResMed financial flexibility to fund M&A, product investment, and capital returns. This cash strength reduces refinancing risk and supports multi-year strategy execution even if growth moderates.
Recurring Consumables + Software Ecosystem With GLP‑1 Demand TailwindA large installed base driving repeat consumable purchases and subscription software creates durable recurring revenue and high lifetime value. Clinical evidence linking GLP‑1 use to higher resupply amplifies structural demand for masks and supplies, strengthening long-term revenue resilience and cross-sell potential.
Bears Say
RCS (Residential Care Software) UnderperformanceUnderperformance in the RCS vertical impairs a key part of ResMed's strategy to expand software recurring revenue and higher-margin services. Persistent weakness in senior living/long‑term care could slow overall margin expansion and reduce the anticipated recurring revenue runway absent successful portfolio fixes.
Rising SG&A And R&D Investment PressureSustained above-trend increases in SG&A and R&D can compress operating leverage and limit margin upside from revenue growth. While investments may drive future product and market gains, if productivity or returns lag, higher structural opex could slow EPS growth versus revenue and constrain free cash flow conversion.
Component Cost And Reimbursement/channel RisksInput-cost inflation and volatile logistics can erode gross margins if not fully offset by price or productivity gains. Separately, reimbursement variability for premium fabric masks creates structural channel risk: constrained HME economics or uneven payer coverage could limit adoption and recurring consumables revenue in specific markets.
RMD FAQ
What was Resmed Inc’s price range in the past 12 months?
Resmed Inc lowest stock price was $180.26 and its highest was $293.81 in the past 12 months.
What is Resmed Inc’s market cap?
Resmed Inc’s market cap is $28.27B.
When is Resmed Inc’s upcoming earnings report date?
Resmed Inc’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Resmed Inc’s earnings last quarter?
Resmed Inc released its earnings results on Apr 30, 2026. The company reported $2.86 earnings per share for the quarter, beating the consensus estimate of $2.795 by $0.065.
Is Resmed Inc overvalued?
According to Wall Street analysts Resmed Inc’s price is currently Undervalued.
Does Resmed Inc pay dividends?
Resmed Inc pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.92%. See more information on Resmed Inc dividends here
What is Resmed Inc’s EPS estimate?
Resmed Inc’s EPS estimate is 2.9.
How many shares outstanding does Resmed Inc have?
Resmed Inc has 145,056,380 shares outstanding.
What happened to Resmed Inc’s price movement after its last earnings report?
Resmed Inc reported an EPS of $2.86 in its last earnings report, beating expectations of $2.795. Following the earnings report the stock price went down -4.111%.
Which hedge fund is a major shareholder of Resmed Inc?
Currently, no hedge funds are holding shares in RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$256.09 (12.26% Upside)
$256.09 (12.26% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 15.2%
Last 30 Days ▼ 15.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.72%
12-Months-Change
Fundamentals
Return on Equity
24.41%
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Company Description
Resmed Inc
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
RMD Company Deck
RMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: durable revenue growth (11% headline, 8% constant), material gross margin expansion (+290 bps YoY), double‑digit EPS growth (~21%), strong free cash flow and capital returns, successful product rollouts (fabric masks, AirSense 11) and large real‑world evidence supporting a GLP‑1 demand tailwind. Management acknowledged and is actively managing a set of medium‑term headwinds — including rising SG&A and R&D investments, isolated investment write‑downs, RCS vertical challenges, component cost pressures, and near‑term acquisition dilution — but positioned these as manageable given a strong balance sheet, ongoing supply chain productivity initiatives, and targeted M&A.View all RMD earnings summariesRMD Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service

RMD Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$256.09
▲(12.26% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
0.53% Insiders
16.74% Mutual Funds
11.12% Other Institutional Investors
42.47% Public Companies and Individual Investors












